Minding the gap – Heterogeneity of antithrombotic treatment preferences in complex scenarios in absence of evidence-based guidelines

Gaps in clinical evidence make contemporary clinical decision-making and patient management challenging. Due to the natural lag time between establishment and implementation of new treatment guidelines run the gamut from first consensus through the relevant medical associations and university medical departments before entering routine care in peripheral institutions and clinics. The dilemma is particularly evident in the case of antithrombotics, which bear the risk of severe adverse bleeding. Antithrombotic treatment is a cornerstone for the clinical management of patients with coronary artery disease (CAD) and atrial fibrillation (AF), which both feature a prothrombotic state, albeit by different mechanisms.